Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale
The DOI matches its Crossref record.
Abstract
Relatively little research has focused on the relationship between functional remission and symptomatic remission in mood and anxiety disorders. This study investigates the relationship and synchrony between symptomatic and functional remission in outpatients with major depressive disorder (MDD) and generalized anxiety disorder (GAD). Using data from three MDD (N=1419) and four GAD (N=1847) randomized, placebo-controlled duloxetine studies, we calculated the percentages of patients meeting symptomatic, functional, and combined functional-symptomatic remission criteria for each disorder. We also calculated mean depression [17-item Hamilton depression rating scale (HAMD₁₇), Montgomery-Asberg depression rating scale] scores and mean anxiety (Hamilton anxiety rating scale) scores for patients meeting Sheehan disability scale (SDS) functional remission and the mean SDS scores for patients with symptomatic remission. Among the patients with MDD, 38% achieved symptomatic remission (HAMD₁₇ ≤ 7), 32% achieved functional remission (SDS ≤ 6), and 23% achieved combined functional-symptomatic remission. Mean HAMD₁₇ and Montgomery-Asberg depression rating scale scores for patients with functional remission were approximately 6. Mean SDS total scores for patients with symptomatic remission were 7.1 (patients with HAMD₁₇ ≤ 7) and 8.6 (patients with Montgomery-Asberg depression rating scale ≤ 10). Among the patients with GAD, 30% achieved symptomatic remission (Hamilton anxiety rating scale ≤ 7), 45% achieved functional remission (SDS ≤ 6), and 25% achieved combined symptomatic-functional remission. The mean Hamilton anxiety rating scale score in GAD was approximately 8 for patients with functional remission and the mean SDS total score was approximately 4 in patients with symptomatic remission. The study shows that functional remission does not always move in tandem with symptom remission and provides useful anchor points or rules of thumb for evaluating symptomatic and functional remission in MDD and GAD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MDD patients have lower remission rates due to cognitive impairment.5”
Citations
Cites
Still being checked.
Cited by
Items 101–124 of 124
Osweiler, B. W., Lew, D., Lv, N., Ma, J., & Kannampallil, T. (2025) · PLoS ONE · doi:10.1371/journal.pone.0328715 · Cited by 2
Masand, P. S., Parikh, M., Ta, J. T., Zanardo, E., Lejeune, D., Martínez, C., Laliberté, F., & Nabulsi, N. A. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2470014 · Cited by 2
Takım, U., Gökçay, H., & Sağlam, T. (2025) · World Journal of Psychiatry · doi:10.5498/wjp.v15.i12.112601 · Cited by 3
Toyoshima, K., Inoue, T., Shimura, A., Uchida, Y., Masuya, J., Fujimura, Y., Higashi, S., & Kusumi, I. (2021) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2021.100180 · Cited by 2
Cutler, A. J., Gommoll, C., Chen, C., Greenberg, W. M., & Ruth, A. (2015) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.14m01753 · Cited by 2
Affective temperaments and functional disability modulate depressive symptoms in adulthood
Toyoshima, K., Inoue, T., Masuya, J., Fujimura, Y., Higashi, S., & Kusumi, I. (2021) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2021.100108 · Cited by 2
Toyoshima, K., Inoue, T., Masuya, J., Fujimura, Y., Higashi, S., & Kusumi, I. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.02.144 · Cited by 1
Masand, P. S., Parikh, M., Ta, J. T., Wade, S. W., Haile, F., Ripley, S., Zanardo, E., Spencer, C., Laliberté, F., & Nabulsi, N. A. (2025) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s522756 · Cited by 1
A systemic and dialectical paradigm for Psychoneuroendocrineimmunology and integrated care science
Bottaccioli, F., & Bottaccioli, A. G. (2025) · Brain Behavior and Immunity Integrative · doi:10.1016/j.bbii.2025.100138 · Cited by 1
A systemic and dialectical paradigm for Psychoneuroendocrineimmunology and integrated care science
Bottaccioli, F., & Bottaccioli, A. G. (2026) · PNEI REVIEW · doi:10.3280/pnei2025oa21668 · Cited by 1
Aronica, R., Pagani, C., Favalli, V., Brambilla, P., Nosari, G., & Delvecchio, G. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.03.197 · Cited by 4
Trajectories of Function and Symptom Change in Desvenlafaxine Clinical Trials
Zilcha‐Mano, S., Wang, X., Wajsbrot, D., Boucher, M., Fine, S. A., & Rutherford, B. R. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001435 · Cited by 2
Porcu, M., Urbano, M. R., Verri, W. A., Jr., Machado, R. C. R., Vargas, H. O., & Nunes, S. O. V. (2022) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2022.100336 · Cited by 3
Wang, J., Yuan, M., & Zhang, W. (2022) · PubMed Central · doi:10.12182/20220960509 · Cited by 3
A general measure of domain-specific quality of life and functional impairment
Roley‐Roberts, M. E. (2013) · OhioLink ETD Center (Ohio Library and Information Network)
Mittal, S., & Raulgaonkar, H. (2019) · International Journal of Business and Economics Research · doi:10.11648/j.ijber.20190803.13
González‐Blanch, C., Medrano, L. A., Ruiz‐Rodríguez, P., Muñoz‐Navarro, R., Moriana, J. A., & Vindel, A. C. (2023) · Cognitive Therapy and Research · doi:10.1007/s10608-023-10360-1
Oshibuchi, H., Nakamura, H., Yoshida, K., Ishigooka, J., & Nishimura, K. (2025) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2025.2560353
Wong, V. W.-H., Shi, N.-K., Lee, L., Chan, S. W. Y., Ng, C. H., Sarris, J. J., & Ho, F. Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-21688-x
Stein, D. J., Kazdin, A. E., Ruscio, A. M., Chiu, W. T., Sampson, N. A., Ziobrowski, H. N., Aguilar‐Gaxiola, S., Al-Hamzawi, A. A., Alonso, J., Altwaijri, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15139469
Papalexi, E., Galanopoulos, A., Kontis, D., Markopoulou, M., Balta, G., Karavelas, E., Panagiotidis, P., Vlachos, T., & Ettrup, A. (2022) · Figshare · doi:10.6084/m9.figshare.20484658
Lodovico, L. D., Westphalen, C., du Montcel, C. T., Tertre, L. L., Courtet, P., & Gorwood, P. A. P. M. (2026) · Psychotherapy and Psychosomatics · doi:10.1159/000553379
Bahremand, A., Maheu, S., Miniaoui, M., Stip, É., Cailhol, L., Pinard, G.-F., Do, A., & Armoon, B. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122471
Metadata
- Authors
- Sheehan, D. V., Harnett-Sheehan, K., Spann, M. E., Thompson, H. F., & Prakash, A.
- Affiliations
- University of South Florida (US)
- Alcon (United States) (US)
- Eli Lilly (United States) (US)
- Corresponding author
- Prakash, Apurva
- ORCID
- Sheehan, David V.
- Venue
- International Clinical Psychopharmacology
- Published
- 2011-03
- Volume
- 26
- Issue
- 2
- Pages
- 75-83
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2025491005
- Cited by
- 124
- References
- 0
- Citations by year
- 2026: 3 · 2025: 16 · 2024: 10 · 2023: 7 · 2022: 14 · 2021: 9 · 2020: 11 · 2019: 7 · 2018: 11 · 2017: 12 · 2016: 2 · 2015: 8 · 2014: 5 · 2013: 7 · 2012: 2
- FWCI
- 2.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Mental Health Research Topics
- Keywords
- functional remission, symptom remission, major depressive disorder, generalized anxiety disorder, Sheehan Disability Scale, duloxetine, outpatients, remission assessment, mood and anxiety disorders, Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale
- MeSH terms
- Duloxetine Hydrochloride, Antidepressive Agents, Anxiety Disorders, Depression, Major Depressive Disorder, Double-Blind Method, Humans, Outpatients, Placebos, Psychiatric Status Rating Scales, Psychometrics, Thiophenes, Time Factors, Comorbidity, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.